The global high potency API contract manufacturing market garnered a market value of US$ 8 Billion in 2022 and is expected to accumulate a market value of US$ 16 Billion by registering a CAGR of 7% in the forecast period 2022 to 2032. Because of the rising frequency of cancer cases globally, the usage of HPAPIs is increasing, which is driving the market.
Furthermore, the government is sponsoring therapeutic substance development and research, which is expected to fuel the growth of the high-potency API contract manufacturing market. As a result of the high investment funds required for manufacturing and production facilities, contract product manufacturing is being used. During the forecast period, this will drive the global market.
Increasing demand for pharmaceuticals, a greater emphasis on precision medicine and high-potency APIs, and technological developments in high-potency API production are some of the reasons driving market expansion.
The International Agency for Research on Cancer (IARC) has revised GLOBOCAN 2020 with new cancer burden projections, predicting that the cancer burden would increase to 19.3 million cases and 10 million cancer deaths in 2020. According to this new study, more than 50 million individuals will be diagnosed with cancer within the next five years. The utilization of high-potency API in various medicinal regimens is also contributing to market expansion.
For example, in 2020, the USA Center for Drug Evaluation and Research (CDER) authorized novel medicines for several malignancies, including lung, thyroid, and breast cancer. Small and big API molecules were used in these treatments. These medications' major ingredients are high-potency APIs. With an increasing number of cancer cases, the market for cancer treatment will expand in tandem.
| Data Points | Key Statistics |
|---|---|
| Estimated Base Year Value (2021) | US$ 6.5 Billion |
| Expected Market Value (2022) | US$ 8 Billion |
| Anticipated Forecast Value (2032) | US$ 16 Billion |
| Projected Growth Rate (2022 to 2032) | 7% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for high potency API contract manufacturing is projected to increase at a CAGR of 7% during the forecast period between 2022 and 2032, reaching a total of US$ 16 Billion in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 5%.
The increased demand for outsourcing HPAPI manufacture, as well as a robust pipeline of targeted therapeutic medications, is projected to drive the growth of the market. However, the concentration of technological expertise in the hands of a few significant companies, as well as the absence of uniform regulatory regulations and standards, are expected to drive the growth of the market.
Other factors driving market expansion include rising demand for antibody-drug conjugates and cancer treatments. Furthermore, the approval of government regulations for the development and manufacture of innovative medicine is expected to boost market growth throughout the forecast period.
Patent Expiration of Blockbuster Drugs to Open New Growth Frontiers
The expiration of patents and subsequent launch of generic versions is a major boon for pharmaceutical businesses to extend their product portfolios and enter attractive market niches in this technology-driven industry. Several biosimilars have been authorized in Europe, however, the US FDA has only approved one biosimilar yet. Increased research and development operations, as well as ongoing attempts to replicate branded biological medications, would pave the way for the introduction of cost-effective therapeutic options.
Several blockbuster pharmaceuticals are projected to lose their patent protection in the near future, opening up significant prospects in the biosimilar industry. Some of the key medications that will go off patent in the near future are Avastin (bevacizumab), Herceptin (trastuzumab), Synagis (palivizumab), Erbitux (cetuximab), Humira (adalimumab), Remicade (infliximab), and Rituxan (rituximab).
Growing need for Outsourcing HPAPI Manufacturing, as well as a robust pipeline of Targeted Therapeutic Medications
Pharmaceutical firms were hesitant to outsource the production of high-potency APIs; hence the vast bulk of production remained captive or in-house. The fear of patent violation was a major motivator. However, when pharmaceutical businesses began to grow geographically, they began to run out of HPAPIs.
Furthermore, rising medication development and commercialization costs increased the financial strain. With the evolving regulatory and legal environment, outsourcing has proven to be the best alternative for HPAPI manufacture.
Principal Consultant
The concentration of Technical Expertise across a handful of Players is causing Market Disruption
Manufacturing high-potency APIs is capital-demanding and needs specialized technical know-how; this has been a key obstacle for new players seeking to enter the lucrative HPAPI business. There are now just a few large companies that have established their own capabilities through mergers, acquisitions, collaborations, and Research and Development (R&D).
A host of Medicines in the Pipeline to bolster prospects for API Contract Manufacturing
The Asia Pacific region is predicted to develop at the quickest rate throughout the projection period. The expanding spectrum of prospects, particularly in Japan, China, and India, can be linked to the expansion.
Factors like as a better regulatory environment, a large potential for cost reductions, enhanced risk management skills, and a healthy medication pipeline are projected to boost the region's growth in the coming years. Furthermore, the availability of qualified labor at cheaper prices than in established nations such as the United States is expected to accelerate regional market growth.
Rising Incidence of Illnesses such as Cancer and Neurological Problems to Accelerate Market Growth
During the projection period, North America is likely to have a large market share, estimated at around 38% by 2022-end. With the incidence of illnesses such as cancer and neurological problems, the United States was the most impacted country in the world. As the incidence of these illnesses rises, so will the region's output of HPAPIs.
HPAPIs are frequently employed in cancer and other major diseases therapeutic, drug development, and other research activities. As a result, the demand for the same will be substantially larger in the North American area, where the patient population is growing faster than in other countries. Because of its growing elderly population and increased prevalence and incidence of infectious illnesses, North America is likely to dominate the high-potency APIs/HPAPI market.
Chronic disorders, such as cancer, are also prevalent in the United States. According to the American Cancer Society journal's 2020 report, there will be an estimated 1.8 million new cancer cases diagnosed and 606,520 cancer deaths in 2020. According to the Parkinson's Foundation's 2020 estimates, around 1 million individuals in the United States have Parkinson's disease, which is greater than the total number of persons diagnosed with muscular dystrophy, multiple sclerosis, and Amyotrophic Lateral Sclerosis. By 2030, this figure is predicted to rise to 1.2 million.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Oncology to be a promising Field for High Potency API Contract Manufacturing
According to Future Market Insights, major developments are expected to happen in the oncology segment with regard to high-potency API contract manufacturing. The rising number of cancer cases worldwide is the primary driver of this market. For example, The Cancer Atlas predicts that there will be 29 million cancer diagnoses by 2040, up from over 18 million in 2018. Furthermore, unlike traditional, systemic treatments, some new cancer medicines in development are exceedingly precise.
Antibody-drug conjugates, which can have occupational exposure levels, and monoclonal antibodies coupled with small molecule cytotoxic chemicals are examples of such targeted HPAPIs. Because of the fast increase of cancer targets, the fraction of HPAPI applications in the therapeutic pipeline is rapidly growing. As per the report, oncology likely accounts for over 63% of all high-potency API contract manufacturing operations.
Demand for Injectables to witness a Steady Incline in Forthcoming Years
The global industry has been subdivided into Injectables, oral solids, lotions, and others based on dosage forms. In 2021, the injectable dosage form sector led the worldwide industry, comprising over 50% of global revenues.
The category is expected to grow at a stable CAGR, maintaining its dominance throughout the projected years. The speedy delivery of HPAPI to the intended area can be credited to the segment's rise. They can be administered subcutaneously (in the fat layer), intradermally (between the layers of skin), or intramuscularly (in the muscle).
Key players in the High Potency API Contract Manufacturing market are Piramal Pharma Solutions, Lonza, Catalent, Inc., VxP Pharma, Inc., Pfizer CentreOne, Gentec Pharmaceutical Group, AbbVie, Aurigene Pharmaceutical Services Ltd., CordenPharma International, and Curia Global, Inc.
Recent Developments:
| Report Attribute | Details |
|---|---|
| Market Value in 2022 | US$ 8 Billion |
| Market Value in 2032 | US$ 16 Billion |
| Growth Rate | CAGR of 7% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2017 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in US$ Billion and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
FMI projects the global High Potency API Contract Manufacturing market to expand at a 7% value CAGR by 2032
The global high potency API contract manufacturing market is estimated at a market value of US$ 8 Billion
The global High Potency API Contract Manufacturing market is expected to garner a market value of US$ 16 Billion
Piramal Pharma Solutions, Lonza, Catalent, Inc., VxP Pharma, Inc., Pfizer CentreOne, Gentec Pharmaceutical Group, AbbVie, Aurigene Pharmaceutical Services Ltd., CordenPharma International and Curia Global, Inc., are some prominent High Potency API Contract Manufacturing manufacturers.
The oncology segment is expected to hold the largest market share for High Potency API Contract Manufacturing in the forecast period 2022 to 2032.
1. Executive Summary | High Potency API Contract Manufacturing Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ million) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Product Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ million) Analysis By Product Type, 2017 to 2021
5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Product Type, 2022 to 2032
5.3.1. Innovative
5.3.2. Generic
5.4. Y-o-Y Growth Trend Analysis By Product Type, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Product Type, 2022 to 2032
6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Synthesis
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ million) Analysis By Synthesis, 2017 to 2021
6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Synthesis, 2022 to 2032
6.3.1. Synthetic
6.3.2. Biotech
6.4. Y-o-Y Growth Trend Analysis By Synthesis, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By Synthesis, 2022 to 2032
7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Application
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ million) Analysis By Application, 2017 to 2021
7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Application, 2022 to 2032
7.3.1. Oncology
7.3.2. Hormonal Disorders
7.3.3. Glaucoma
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By Application, 2017 to 2021
7.5. Absolute $ Opportunity Analysis By Application, 2022 to 2032
8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Dosage Form
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ million) Analysis By Dosage Form, 2017 to 2021
8.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Dosage Form, 2022 to 2032
8.3.1. Injectable
8.3.2. Oral Solids
8.3.3. Creams
8.3.4. Others
8.4. Y-o-Y Growth Trend Analysis By Dosage Form, 2017 to 2021
8.5. Absolute $ Opportunity Analysis By Dosage Form, 2022 to 2032
9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ million) Analysis By Region, 2017 to 2021
9.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2022 to 2032
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. Middle East and Africa (MEA)
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. The USA
10.2.1.2. Canada
10.2.2. By Product Type
10.2.3. By Synthesis
10.2.4. By Application
10.2.5. By Dosage Form
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product Type
10.3.3. By Synthesis
10.3.4. By Application
10.3.5. By Dosage Form
10.4. Key Takeaways
11. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Product Type
11.2.3. By Synthesis
11.2.4. By Application
11.2.5. By Dosage Form
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product Type
11.3.3. By Synthesis
11.3.4. By Application
11.3.5. By Dosage Form
11.4. Key Takeaways
12. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. The United Kingdom
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Product Type
12.2.3. By Synthesis
12.2.4. By Application
12.2.5. By Dosage Form
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product Type
12.3.3. By Synthesis
12.3.4. By Application
12.3.5. By Dosage Form
12.4. Key Takeaways
13. South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Product Type
13.2.3. By Synthesis
13.2.4. By Application
13.2.5. By Dosage Form
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product Type
13.3.3. By Synthesis
13.3.4. By Application
13.3.5. By Dosage Form
13.4. Key Takeaways
14. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
14.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
14.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Product Type
14.2.3. By Synthesis
14.2.4. By Application
14.2.5. By Dosage Form
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product Type
14.3.3. By Synthesis
14.3.4. By Application
14.3.5. By Dosage Form
14.4. Key Takeaways
15. Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
15.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
15.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Product Type
15.2.3. By Synthesis
15.2.4. By Application
15.2.5. By Dosage Form
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Product Type
15.3.3. By Synthesis
15.3.4. By Application
15.3.5. By Dosage Form
15.4. Key Takeaways
16. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
16.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
16.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Product Type
16.2.3. By Synthesis
16.2.4. By Application
16.2.5. By Dosage Form
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Product Type
16.3.3. By Synthesis
16.3.4. By Application
16.3.5. By Dosage Form
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. The USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2021
17.1.2.1. By Product Type
17.1.2.2. By Synthesis
17.1.2.3. By Application
17.1.2.4. By Dosage Form
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2021
17.2.2.1. By Product Type
17.2.2.2. By Synthesis
17.2.2.3. By Application
17.2.2.4. By Dosage Form
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2021
17.3.2.1. By Product Type
17.3.2.2. By Synthesis
17.3.2.3. By Application
17.3.2.4. By Dosage Form
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2021
17.4.2.1. By Product Type
17.4.2.2. By Synthesis
17.4.2.3. By Application
17.4.2.4. By Dosage Form
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2021
17.5.2.1. By Product Type
17.5.2.2. By Synthesis
17.5.2.3. By Application
17.5.2.4. By Dosage Form
17.6. The United Kingdom
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2021
17.6.2.1. By Product Type
17.6.2.2. By Synthesis
17.6.2.3. By Application
17.6.2.4. By Dosage Form
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2021
17.7.2.1. By Product Type
17.7.2.2. By Synthesis
17.7.2.3. By Application
17.7.2.4. By Dosage Form
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2021
17.8.2.1. By Product Type
17.8.2.2. By Synthesis
17.8.2.3. By Application
17.8.2.4. By Dosage Form
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2021
17.9.2.1. By Product Type
17.9.2.2. By Synthesis
17.9.2.3. By Application
17.9.2.4. By Dosage Form
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2021
17.10.2.1. By Product Type
17.10.2.2. By Synthesis
17.10.2.3. By Application
17.10.2.4. By Dosage Form
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2021
17.11.2.1. By Product Type
17.11.2.2. By Synthesis
17.11.2.3. By Application
17.11.2.4. By Dosage Form
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2021
17.12.2.1. By Product Type
17.12.2.2. By Synthesis
17.12.2.3. By Application
17.12.2.4. By Dosage Form
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2021
17.13.2.1. By Product Type
17.13.2.2. By Synthesis
17.13.2.3. By Application
17.13.2.4. By Dosage Form
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2021
17.14.2.1. By Product Type
17.14.2.2. By Synthesis
17.14.2.3. By Application
17.14.2.4. By Dosage Form
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2021
17.15.2.1. By Product Type
17.15.2.2. By Synthesis
17.15.2.3. By Application
17.15.2.4. By Dosage Form
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2021
17.16.2.1. By Product Type
17.16.2.2. By Synthesis
17.16.2.3. By Application
17.16.2.4. By Dosage Form
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2021
17.17.2.1. By Product Type
17.17.2.2. By Synthesis
17.17.2.3. By Application
17.17.2.4. By Dosage Form
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2021
17.18.2.1. By Product Type
17.18.2.2. By Synthesis
17.18.2.3. By Application
17.18.2.4. By Dosage Form
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2021
17.19.2.1. By Product Type
17.19.2.2. By Synthesis
17.19.2.3. By Application
17.19.2.4. By Dosage Form
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2021
17.20.2.1. By Product Type
17.20.2.2. By Synthesis
17.20.2.3. By Application
17.20.2.4. By Dosage Form
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2021
17.21.2.1. By Product Type
17.21.2.2. By Synthesis
17.21.2.3. By Application
17.21.2.4. By Dosage Form
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Product Type
18.3.3. By Synthesis
18.3.4. By Application
18.3.5. By Dosage Form
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Piramal Pharma Solutions
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Lonza
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Catalent, Inc.
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. VxP Pharma, Inc.
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Pfizer CentreOne
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Gentec Pharmaceutical Group
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. AbbVie
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Aurigene Pharmaceutical Services Ltd.
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. CordenPharma International
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Curia Global, Inc.
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Technology
January 2024
REP-GB-15531
315 pages
Healthcare
June 2023
REP-GB-13025
273 pages
Explore Healthcare Insights
View Reports
High Potency API Contract Manufacturing Market
